Search Results - "Pavlick, Anne"

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 by RIMAWI, Mothaffar F, MAYER, Ingrid A, SCHIFF, Rachel, KENT OSBORNE, C, CHANG, Jenny C, FORERO, Andres, NANDA, Rita, GOETZ, Matthew P, RODRIGUEZ, Angel A, PAVLICK, Anne C, TAO WANG, HILSENBECK, Susan G, GUTIERREZ, Carolina

“…We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway…”
Get full text

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models by XIAOMEI ZHANG, CLAERHOUT, Sofie, HELEN WONG, FUQUA, Suzanne W, CONTRERAS, Alejandro, GUTIERREZ, Carolina, JIAN HUANG, SUFENG MAO, PAVLICK, Anne C, FROEHLICH, Amber M, WU, Meng-Fen, TSIMELZON, Anna, PRATT, Aleix, HILSENBECK, Susan G, CHEN, Edward S, ZULOAGA, Pavel, SHAW, Chad A, RIMAWI, Mothaffar F, PEROU, Charles M, MILLS, Gordon B, CHANG, Jenny C, LEWIS, Michael T, DOBROLECKI, Lacey E, PETROVIC, Ivana, QING LAI, LANDIS, Melissa D, WIECHMANN, Lisa, SCHIFF, Rachel, GIULIANO, Mario

“…Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that…”
Get full text

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade by Prat, Aleix, Pascual, Tomás, De Angelis, Carmine, Gutierrez, Carolina, Llombart-Cussac, Antonio, Wang, Tao, Cortés, Javier, Rexer, Brent, Paré, Laia, Forero, Andres, Wolff, Antonio C, Morales, Serafín, Adamo, Barbara, Brasó-Maristany, Fara, Vidal, Maria, Veeraraghavan, Jamunarani, Krop, Ian, Galván, Patricia, Pavlick, Anne C, Bermejo, Begoña, Izquierdo, Miguel, Rodrik-Outmezguine, Vanessa, Reis-Filho, Jorge S, Hilsenbeck, Susan G, Oliveira, Mafalda, Dieci, Maria Vittoria, Griguolo, Gaia, Fasani, Roberta, Nuciforo, Paolo, Parker, Joel S, Conte, PierFranco, Schiff, Rachel, Guarneri, Valentina, Osborne, C Kent, Rimawi, Mothaffar F

“…Abstract Background Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a…”
Get full text

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features by Creighton, Chad J, Li, Xiaoxian, Landis, Melissa, Dixon, J. Michael, Neumeister, Veronique M, Sjolund, Ashley, Rimm, David L, Wong, Helen, Rodriguez, Angel, Herschkowitz, Jason I, Fan, Cheng, Zhang, Xiaomei, He, Xiaping, Pavlick, Anne, Gutierrez, M. Carolina, Renshaw, Lorna, Larionov, Alexey A, Faratian, Dana, Hilsenbeck, Susan G, Perou, Charles M, Lewis, Michael T, Rosen, Jeffrey M, Chang, Jenny C

“…Some breast cancers have been shown to contain a small fraction of cells characterized by CD44⁺/CD24⁻/low cell-surface antigen profile that have high…”
Get full text

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer by Rimawi, Mothaffar F., De Angelis, Carmine, Contreras, Alejandro, Pareja, Fresia, Geyer, Felipe C., Burke, Kathleen A., Herrera, Sabrina, Wang, Tao, Mayer, Ingrid A., Forero, Andres, Nanda, Rita, Goetz, Matthew P., Chang, Jenny C., Krop, Ian E., Wolff, Antonio C., Pavlick, Anne C., Fuqua, Suzanne A. W., Gutierrez, Carolina, Hilsenbeck, Susan G., Li, Marilyn M., Weigelt, Britta, Reis-Filho, Jorge S., Kent Osborne, C., Schiff, Rachel

“…Purpose Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by…”
Get full text

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy by Giuliano, Mario, Hu, Huizhong, Wang, Yen-Chao, Fu, Xiaoyong, Nardone, Agostina, Herrera, Sabrina, Mao, Sufeng, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Hilsenbeck, Susan G, De Angelis, Carmine, Wang, Nicholas J, Heiser, Laura M, Gray, Joe W, Lopez-Tarruella, Sara, Pavlick, Anne C, Trivedi, Meghana V, Chamness, Gary C, Chang, Jenny C, Osborne, C Kent, Rimawi, Mothaffar F, Schiff, Rachel

“…To investigate the direct effect and therapeutic consequences of epidermal growth factor receptor 2 (HER2)-targeting therapy on expression of estrogen receptor…”
Get full text

A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer by Veeraraghavan, Jamunarani, Gutierrez, Carolina, De Angelis, Carmine, Davis, Robert, Wang, Tao, Pascual, Tomas, Selenica, Pier, Sanchez, Katherine, Nitta, Hiroaki, Kapadia, Monesh, Pavlick, Anne C, Galvan, Patricia, Rexer, Brent, Forero-Torres, Andres, Nanda, Rita, Storniolo, Anna M, Krop, Ian E, Goetz, Matthew P, Nangia, Julie R, Wolff, Antonio C, Weigelt, Britta, Reis-Filho, Jorge S, Hilsenbeck, Susan G, Prat, Aleix, Osborne, C Kent, Schiff, Rachel, Rimawi, Mothaffar F

“…Clinical trials reported 25% to 30% pathologic complete response (pCR) rates in HER2+ patients with breast cancer treated with anti-HER2 therapies without…”
Get full text

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy by De Angelis, Carmine, Nagi, Chandandeep, Hoyt, Cliff C, Liu, Linying, Roman, Kristin, Wang, Chichung, Zheng, Yi, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Nuciforo, Paolo, Wang, Tao, Tsimelzon, Anna, Mao, Sufeng, Hilsenbeck, Susan G, Trivedi, Meghana V, Cataldo, Maria Letizia, Pavlick, Anne, Wolff, Antonio C, Weigelt, Britta, Reis-Filho, Jorge S, Prat, Aleix, Gutierrez, Carolina, Osborne, Charles Kent, Rimawi, Mothaffar F, Schiff, Rachel

“…Tumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2 breast cancer. The…”
Get full text

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy by Li, Xiaoxian, Lewis, Michael T., Huang, Jian, Gutierrez, Carolina, Osborne, C. Kent, Wu, Meng-Fen, Hilsenbeck, Susan G., Pavlick, Anne, Zhang, Xiaomei, Chamness, Gary C., Wong, Helen, Rosen, Jeffrey, Chang, Jenny C.

“…Background Tumorigenic breast cancer cells that express high levels of CD44 and low or undetectable levels of CD24 (CD44>/CD24>/low) may be resistant to…”
Get full text

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer by Rimawi, Mothaffar F, Niravath, Polly, Wang, Tao, Rexer, Brent N, Forero, Andres, Wolff, Antonio C, Nanda, Rita, Storniolo, Anna M, Krop, Ian, Goetz, Matthew P, Nangia, Julie R, Jiralerspong, Sao, Pavlick, Anne, Veeraraghavan, Jamunarani, De Angelis, Carmine, Gutierrez, Carolina, Schiff, Rachel, Hilsenbeck, Susan G, Osborne, C Kent

“…Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients…”
Get full text

Abstract P5-14-02: Breast cancer clinical trial participation rate among patients of low socioeconomic status at a comprehensive cancer center by Shafaee, Maryam Nemati, Podany, Emily L, Sanchez, Katherine, Higashiyama, Nicole, Hoyos, Valentina, Micheal, Liz Binu, Otte, Kristen, Pavlick, Anne, Nangia, Julie, Kuriakose, Alphi, Osborne, Kent C, Jibaja-Weiss, Maria, Ellis, Matthew J, Bulsara, Shaun, Rimawi, Mothaffar

“…Abstract Background: Patients with higher socioeconomic status (SES) are overrepresented in NCI-sponsored cancer clinical trials (CCT). Inadequate access,…”
Get full text

Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia by Niravath, Polly, Hilsenbeck, Susan G., Wang, Tao, Jiralerspong, Sao, Nangia, Julie, Pavlick, Anne, Ademuyiwa, Foluso, Frith, Ashley, Ma, Cynthia, Park, Haeseong, Rigden, Caron, Suresh, Rama, Ellis, Matthew, Kent Osborne, C., Rimawi, Mothaffar F.

“…Purpose Half of hormone receptor-positive (HR+) breast cancer patients will develop joint pain, termed aromatase inhibitor-induced arthralgia (AIA), while…”
Get full text

Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy by De Angelis, Carmine, Nagi, Chandandeep, Hoyt, Cliff C., Liu, Linying, Roman, Kristin, Wang, Chichung, Zheng, Yi, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Nuciforo, Paolo, Wang, Tao, Tsimelzon, Anna, Mao, Sufeng, Hilsenbeck, Susan G., Trivedi, Meghana V., Cataldo, Maria Letizia, Pavlick, Anne C., Wolff, Antonio C., Weigelt, Britta, Reis-Filho, Jorge S., Prat, Aleix, Gutierrez, Carolina, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel

Get full text

HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials by Prat, Aleix, De Angelis, Carmine, Pascual, Tomás, Gutierrez, Carolina, Llombart-Cussac, Antonio, Wang, Tao, Cortes, Javier, Rexer, Brent Neil, Veeraraghavan, Jamunarani, Forero-Torres, Andres, Wolff, Antonio C., Morales, Serafin, Krop, Ian E., Pavlick, Anne Clarisse, Bermejo, Begona, Hilsenbeck, Susan G., Oliveira, Mafalda, Schiff, Rachel, Osborne, C. Kent, Rimawi, Mothaffar F.

“…Abstract only…”
Get full text

Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach by Petrosyan, Varduhi, Dobrolecki, Lacey E., Thistlethwaite, Lillian, Lewis, Alaina N., Sallas, Christina, Srinivasan, Ramakrishnan R., Lei, Jonathan T., Kovacevic, Vladimir, Obradovic, Predrag, Ellis, Matthew J., Osborne, C. Kent, Rimawi, Mothaffar F., Pavlick, Anne, Shafaee, Maryam Nemati, Dowst, Heidi, Jain, Antrix, Saltzman, Alexander B., Malovannaya, Anna, Marangoni, Elisabetta, Welm, Alana L., Welm, Bryan E., Li, Shunqiang, Wulf, Gerburg M., Sonzogni, Olmo, Huang, Chen, Vasaikar, Suhas, Hilsenbeck, Susan G., Zhang, Bing, Milosavljevic, Aleksandar, Lewis, Michael T.

“…Although systemic chemotherapy remains the standard of care for TNBC, even combination chemotherapy is often ineffective. The identification of biomarkers for…”
Get full text

Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer by Rimawi, Mothaffar F, Niravath, Polly A, Wang, Tao, Rexer, Brent, Forero, Andres, Wolff, Antonio C, Nanda, Rita, Storniolo, Anna M, Krop, Ian, Goetz, Matthew P, Nangia, Julie R, Jiralerspong, Sao, Pavlick, Anne C, Gutierrez, Carolina, Schiff, Rachel, Hilsenbeck, Susan G, Osborne, C Kent

“…Abstract Background: We have previously shown in animal models that combination anti-HER2 therapy leads to complete tumor regression of HER2+ breast cancer…”
Get full text

Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer by Parma, Jennifer, Pavlick, Anne, Schiff, Rachel, Osborne, C. Kent, Chang, Jenny C., Rimawi, Mothaffar, Trivedi, Meghana V.

“…Study Objective To determine if development of acneiform rash is a predictor of objective response rate with lapatinib. Design Subanalysis of data from a…”
Get full text